OncLive® On Air

S18 Ep15: ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

S18 Ep14: FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

S18 Ep13: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

S18 Ep12: Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua Sabari, MD

Small cell lung cancer requires aggressive, rapid intervention due to its high mortality and rapid progression, with diagnosis and staging ideally occurring within 48 to 72 hours. Dr. Joshua K. Sabari of NYU Langone Health highlights that significant attrition between therapy lines—reaching up to 60% in community setti...

S18 Ep11: Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

S18 Ep10: Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

S18 Ep9: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Antibody-drug conjugates (ADCs) and bispecific antibodies are transforming the treatment landscape for solid tumors by providing targeted options for patients with limited alternatives. In lung cancer, bispecific agents targeting PD-1 and VEGF demonstrate significant efficacy in PD-L1 negative populations, addressing a...

S18 Ep8: DLBCL 2026 UPDATE

S18 Ep7: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

S18 Ep6: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

S18 Ep5: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

S18 Ep4: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Targeted therapies and immunotherapies are transforming the treatment landscape for advanced non-small cell lung cancer by addressing specific genomic alterations and immune evasion mechanisms. ROS1 and RET inhibitors have evolved significantly, with newer agents like talotrectinib and repotrectinib demonstrating super...

S18 Ep3: Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

S18 Ep2: Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

S18 Ep1: RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

S17 Ep50: Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

S17 Ep49: Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

S17 Ep48: FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

S17 Ep47: Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

S17 Ep45: Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care